Furthers Mission to Address Unmet Medical Needs Across the Globe
TAMPA, Florida and ALBANY, New York, June 22, 2016 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot) and Albany Molecular Research, Inc. (NASDAQ: AMRI) today announced that AMRI has licensed Teewinot's technology to produce and sell the first commercially available cannabichromene acid (CBCA) analytical standard. The CBCA analytical standard is manufactured using Teewinot's patented biosynthetic processes. Teewinot's proprietary processes involve the expression of cannabinoid biosynthetic genes in microorganisms for efficient production of large quantities of cannabinoids.
"Interest in capturing the therapeutic value of cannabinoids is on the upswing for basic research as well as for pharmaceutical development," said William Marth, president and CEO of AMRI. "As such, companies will need tools that help them ensure their development programs meet the rigorous requirements for drug development. AMRI is continually evaluating and developing technologies for practical production of new, or difficult to synthesize molecules to enhance efficiency and/or quality."
Cannabinoids have therapeutic potential in a number of areas including oncology, pain relief and inflammation, yet until recently, few companies have pursued their study as therapeutic agents. Efforts to advance cannabinoid compounds into therapeutic development will require rigorous testing for quality, safety and efficacy. This unique analytical standard is one tool that can facilitate research, development, and quality control for pharmaceutical applications of cannabinoids.
"We opted to work with AMRI to scale up the production of our CBCA standard because the company has a global footprint and an exceptional reputation within the field of bioprocess development," said Richard Peet, Teewinot's executive vice president. "Partnering with a leader like AMRI will ensure that the standards available using our biosynthetic platform are consistent and results achieved with them are reproducible."
About Teewinot Life Sciences Corporation
Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on the use of synthetic biology and advanced formulation for the production and implementation of cannabinoid based therapies. With headquarters in Tampa, Florida, Teewinot manufactures and licenses technology to make cost effective, pharmaceutically pure cannabinoids as an industry leader in support of advancing medical research and product development. Teewinot's global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid based medicines. For more information, please follow us on Twitter (@teewinot_corp) or visit www.tlscorp.com.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).